It is a company dedicated to nutraceutics development, pharmacogenetics solutions and research in innovative treatments for lung cancer. The company generates an income of 2,1 million euros.
BioEmprenedorXXI is a joint public-private initiative from “la Caixa”, the Barcelona City Council, Biocat, Genoma España and the Barcelona Chamber of Commerce.
VCN Biosciencies is a spin-off that is devoted to the innovative field of virotherapy, specifically in administering genetically modified viruses to destroy tumor cells.
Ignasi Faus, CEO of Palau Pharma, reveals the keys of their success and gives us his point of view in relation to the BioRegion of Catalonia challenges and potentiality.
